DURHAM, N.C., Jan. 4 /PRNewswire/ -- Serenex, Inc., an integrated oncology-focused drug discovery and development company, announced that Dr. Richard Kent, Chief Executive Officer, is scheduled to present on January 11, 2007 at the 25th Annual JPMorgan Healthcare Conference taking place at the Westin St. Francis Hotel in San Francisco. During the presentation, which will be webcast, Dr. Kent will provide an overview of the company and its ongoing development programs. Specifically, Dr. Kent will review SNX-1012, the company's phase 2 compound for oral mucositis and SNX-5422, the company's novel Hsp90 inhibitor candidate. A replay of the presentation will be available under the "News" section of the Serenex website at http://www.serenex.com.

    The following are specific details of the conference:

    25th Annual JPMorgan Healthcare Conference:
    Date: January 11, 2007
    Time: 8:30 a.m. PST (11:30 a.m. ET)
    Location: Westin St. Francis Hotel, 335 Powell Street, San Francisco, CA
    Room:  Elizabethan C/D

    About Serenex

Serenex is an integrated oncology-focused drug discovery and development company. Serenex's lead program, SNX-1012, a product for chemotherapy and radiation-induced oral mucositis in solid tumor patients, is scheduled to complete phase 2 clinical trials in Q2 2007. Oral mucositis, which represents a large and underserved market, frequently causes clinicians to interrupt therapy which directly leads to decreased rates of efficacy. Serenex's most advanced preclinical-stage program, SNX-5422, is a novel, orally available, small molecule inhibitor of Heat Shock Protein 90. Hsp90 is a central protein responsible for chaperoning a large number of oncogenic proteins (such as Her2 and Raf) that are necessary to support cancer cell survival and growth. SNX- 5422 is scheduled to be at IND in Q1 2007. Serenex's pipeline is powered by a proprietary high throughput screening platform which enables the company to profile compounds, en masse, against thousands of important therapeutic and toxicity targets. Website: www.serenex.com.

SOURCE Serenex, Inc.